Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Company Overview

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases. The company’s lead product candidate, resmetirom (MGL-3196), is an oral, selective thyroid hormone receptor-β agonist designed to reduce liver fat and improve markers of inflammation and fibrosis in patients with NASH. Madrigal is also exploring additional compounds aimed at treating dyslipidemia and cardiovascular risk factors associated with metabolic liver disease.

Since its founding in 2012 and incorporation in Delaware, Madrigal has pursued a strategy of advancing novel, mechanism-based therapies from early discovery through clinical development. The company’s research programs leverage insights into thyroid hormone receptor biology to address underlying drivers of liver injury. Resmetirom has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, reflecting the unmet medical need in NASH and the promising clinical data observed to date.

Madrigal Pharmaceuticals maintains its headquarters in Conshohocken, Pennsylvania, and operates a lean, clinical-focused organization that partners with contract research organizations and academic investigators across North America and Europe. The company’s global approach to clinical trials seeks to enroll a diverse patient population, with ongoing Phase 3 studies evaluating resmetirom’s efficacy and safety in reducing liver fat and improving histological outcomes.

Under the leadership of President and Chief Executive Officer James E. Sapirstein, who joined Madrigal in 2021, the company has strengthened its management team to support late-stage development and regulatory interactions. With a seasoned board of directors and scientific advisory board composed of experts in hepatology and endocrinology, Madrigal remains committed to delivering transformative therapies for patients suffering from metabolic liver diseases.

Key Stats

• Today's Range: $298.00 to $304.00
• 50-Day Range: $267.56 to $340.80
• 52-Week Range: $200.63 to $377.46
• Volume: 108,674 shs
• Average Volume: 358,926 shs
• Market Capitalization: $6.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $420.63
• Consensus Rating: Moderate Buy

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

Madrigal Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 571st out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Madrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($23.47) to ($12.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Madrigal Pharmaceuticals is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Madrigal Pharmaceuticals is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Madrigal Pharmaceuticals has a P/B Ratio of 8.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.81% of the float of Madrigal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Madrigal Pharmaceuticals has recently increased by 6.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Madrigal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Madrigal Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.92

Percentage of Shares Shorted

23.81% of the float of Madrigal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Madrigal Pharmaceuticals has recently increased by 6.68%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.78

News Sentiment

Madrigal Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 5 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.50% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDGL Stock Analysis - Frequently Asked Questions

How have MDGL shares performed this year?

Madrigal Pharmaceuticals' stock was trading at $308.57 at the start of the year. Since then, MDGL stock has decreased by 3.3% and is now trading at $298.4850.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, topping the consensus estimate of ($3.62) by $0.30. The biopharmaceutical company had revenue of $137.25 million for the quarter, compared to the consensus estimate of $112.79 million. Madrigal Pharmaceuticals had a negative trailing twelve-month return on equity of 50.54% and a negative net margin of 123.38%.
Read the conference call transcript.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDGL
• CIK: 1157601
• Web: www.madrigalpharma.com
• Phone: (267) 824-2827
• Fax: 781-274-8228
• Employees: 90
• Year Founded: 2011

Price Target and Rating

• Average Stock Price Target: $420.63
• High Stock Price Target: $469.00
• Low Stock Price Target: $350.00
• Potential Upside/Downside: +40.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($18.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$465.89 million
• Net Margins: -123.38%
• Pretax Margin: -123.38%
• Return on Equity: -50.54%
• Return on Assets: -37.19%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 5.91
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: $180.13 million
• Price / Sales: 36.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.59 per share
• Price / Book: 8.63

Miscellaneous

• Outstanding Shares: 22,200,000
• Free Float: 17,429,000
• Market Cap: $6.63 billion
• Optionable: Optionable
• Beta: -1.05